News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RBCC: New Research Could Massively Expand Market For Addiction Therapy Technology


6/26/2014 10:49:03 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp. (OTCBB: RBCC) works to deliver a new injectable, sustained-release technology poised to vastly improve patients' use of Naltrexone, new research into the drug’s potential could soon dramatically expand the drug’s market and usage. Naltrexone has been approved by the FDA for use in combatting alcohol and heroin addiction by fine-tuning the brain’s chemical rewards system to help reduce cravings. But new research into the drug’s properties has revealed promising applications for the treatment of autoimmune diseases and chronic pain.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES